Robert W. Lash, MD, Named Interim CEO of the Endocrine Society

Version 2

The Endocrine Society has named Robert W. Lash, MD — an endocrinologist with more than 25 years of experience in the field — as its interim CEO.

Lash joined the Society as its Chief Professional & Clinical Affairs Officer in 2017.

“Rob brings a rare depth and breadth of knowledge and experience in endocrinology to the role” says Society President Gary D. Hammer, MD, PhD “His leadership will keep steady our standing as the world’s largest professional endocrine organization, accelerating scientific research and advances in clinical care.”

As a subject matter expert, Lash represents the Society in outreach to scientific and medical societies, policy makers and journalists.

The announcement comes a week before the opening of the Society’s largest-ever meeting, ENDO Online 2020. More than 19,000 people worldwide have registered to attend the virtual event, which will be held June 8-22.

“I am honored to be asked to lead the Society during this time of great challenge and opportunity,” Lash says. “Our Society leaders and staff are proud to be a unifying force supporting our professional community as we navigate these circumstances together.”

Lash spent 20 years at the University of Michigan in Ann Arbor, Mich., where he was a professor of internal medicine at the University’s Medical School and Chief of Staff for Clinical Affairs at Michigan Medicine, the university’s healthcare system.

Earlier in his career, he was assistant professor of internal medicine at the University of Maryland School of Medicine in Baltimore, Md. He did his endocrine fellowship at the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases. As an active Society volunteer, Lash chaired the Clinical Affairs Core Committee.

Lash graduated with his Doctor of Medicine degree from Albert Einstein College of Medicine in New York, N.Y. He earned his Bachelor of Arts degree from Dartmouth College in Hanover, N.H.

The Society has appointed a search committee to select the organization’s next CEO.
 

You may also like

  • Endocrine Society Celebrates Special Diabetes Program Extension

    The Endocrine Society applauds Congress for approving the first funding increase for the Special Diabetes Program in two decades. The U.S. Senate voted Friday March 8 to extend the program, which supports both diabetes care and research into type 1 diabetes, until the end of 2024. This is part of the six-bill package funding several…

  • New Position Statement Focuses on Patient Experience in Diabetes Care

    Healthcare providers who treat diabetes need to think beyond the clinical numbers, such as solely focusing on a person’s glucose goals. Taking the patient experience into account can improve the quality of care and facilitate attainment of treatment goals, according to a new position statement published in the Endocrine Society’s Journal of Clinical Endocrinology &…

Find more in